Sphere Bio has appointed Redbert Biotechnology (张伟) as its exclusive distribution partner in China.  

The deal forms a part of the company’s broader operational scale-up in the APAC region and solidifies its presence in one of the world’s largest and fastest-growing life sciences markets. 

By partnering with Redbert Biotechnology, a specialist bioprocess biotechnology distributor, Sphere Bio hopes to bring its antibody discovery, cell line development, cell engineering and cell therapy solutions to the Chinese market.  

Redbert Biotechnology is strategically located across China with headquarters in Beijing and offices in Shanghai, Shenzhen, Tianjin, Jinan, Chengdu and Nanjing. 

“The Chinese life sciences market is growing at a rapid pace and is spearheading scientific innovation,” said Wei Zhang, CEO, Redbert Biotechnology. “We have been very impressed by Sphere Bio’s technologies, particularly the new Cyto-Mine Chroma platform and its multiplexing capabilities and industry leading throughput. We are excited to be part of the operation to bring these cutting-edge solutions to the Chinese market and realise their potential in accelerating scientific research across Asia.” 

To manage the partnership, Sphere Bio has appointed Johnathan Fu as Country Manager – China and Hong Kong. Fu brings over 19 years of experience specialising in the sales of laboratory instruments, including for 10x Genomics, Roche Diagnostics, and Bio-Rad.  

Dale Levitzke, CEO, Sphere Bio, added: “Penetrating this global market is a significant milestone in our ongoing international growth plans. Together with our broader APAC expansion, under the leadership of Jay Manikandan, these developments are essential for ensuring we continue to proactively respond to market demand, improve customer support, accelerate research and enhance long-term commercial value.”

Diana Spencer, Senior Digital Content Editor, DDW